Novartis and Relation Therapeutics have struck a $1.7 billion collaboration to discover new immuno-dermatology drug targets using Relation’s AI-powered “Lab-in-the-Loop” platform.
Pfizer has forged an exclusive global partnership with YaoPharma to develop and commercialize YP05002, a small-molecule GLP-1 agonist for chronic weight management.
Satellos advances a Phase 2 pediatric DMD trial; Rapid completes DISTALS stroke study; lecanemab gains commercial-insurance access in China; ALS and AD platforms progress.
Freenome is set to become a public company through a SPAC merger with Perceptive Capital Solutions Corp., a deal valuing the multiomics cancer detection developer at roughly $1.1 billion.
China’s latest National Reimbursement Drug List (NRDL), set to take effect on January 1, 2026, is reshaping competitive dynamics across oncology, rare disease, and chronic metabolic care, as a wave of domestic and multinational companies secured new listings or renewed coverage for some of their highest-priority medicines. The update coincides with the release of the … Read more
Merck’s plan to introduce a subcutaneous formulation of Keytruda in Germany has been halted after a Munich court issued a preliminary injunction siding with Halozyme’s patent infringement claims.
A high-momentum day across neuroscience as fresh investment, mechanistic innovation, and late-stage readouts tighten the path from discovery to impact.
The past week delivered a coordinated sequence of moves that, taken together, quietly reset expectations for how global systems will price, approve, pay for, and ultimately adopt innovation in 2026. What distinguished this week was not the volume of news but its consistency: across borders and agencies, decision-makers leaned into a shared posture, broadened access … Read more
Innovent Biologics closed out the year with one of its most consequential access wins to date, securing National Reimbursement Drug List (NRDL) inclusion for seven innovative medicines spanning oncology, immunology, metabolism, and rare disease. The breadth of updates underscores how the company’s maturing R&D engine, lifecycle management strategy, and pricing discipline are converging to generate … Read more
Germany has cleared the way for pharmacy-level substitution of prescribed biologics with lower-cost biosimilars starting in 2026.